Business Segments · Non-cash charges
North American Pharmaceutical — Non-cash charges
McKesson North American Pharmaceutical — Non-cash charges increased by 566.7% to $14.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 3.4%, from $14.50M to $14.00M. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ1 2025
Last reportedQ4 2026May 8, 2026
Rolls up toRestructuring Reserve Settled Without Cash2
How to read this metric
Rising non-cash charges may indicate aging infrastructure or aggressive asset write-downs, while declining charges may suggest reduced capital intensity or completed depreciation cycles.
Detailed definition
Aggregated non-cash expenses, such as depreciation, amortization, and asset impairments, allocated to the North American...
Peer comparison
Standard metric for capital-intensive distribution businesses to assess operational efficiency and asset utilization.
Metric ID:
mck_segment_north_american_pharmaceutical_non_cash_chargesHistorical Data
6 periods
| Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q3 '26 | Q4 '26 | |
|---|---|---|---|---|---|---|
| Value | $14.50M | $14.50M | $14.50M | $14.50M | -$3.00M | $14.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -120.7% | +566.7% |
| YoY Change | — | — | — | — | -120.7% | -3.4% |
Range-$3.00M – $14.50M
CAGR-2.8%
Avg YoY Growth-62.1%
Median YoY Growth-62.1%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's north american pharmaceutical — non-cash charges?
- McKesson (MCK) reported north american pharmaceutical — non-cash charges of $14.00M in Q1 2026.
- How has McKesson's north american pharmaceutical — non-cash charges changed year-over-year?
- McKesson's north american pharmaceutical — non-cash charges decreased by 3.4% year-over-year, from $14.50M to $14.00M.
- What does north american pharmaceutical — non-cash charges mean?
- Total non-cash accounting expenses attributed to the North American pharmaceutical business segment.